01.002 RWE GS Aug 2022 F 18-08-2022

Real-world evidence (RWE) solutions market expected to be worth over $5 billion by 2027

  • Previous forecasts stated that the RWE market was set to grow to being worth over $1 billion by 2023. However, now research shows the market will grow massively in the 4 years following to being worth over $5 billion by 2027. It’s very possible that real-world evidence studies have pushed towards the forefront of research due to the COVID-19 pandemic.
Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.


DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit and contact us at